Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HST101 Phase 3 in Chinese Patients with Hypercholesterolemia
NCT06568471Phase 3Recruiting
- Sponsor
- Hasten Biopharmaceuticals
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing HST101 with Placebo (2 arms). Primary endpoints: LDL-C change compared to Placebo at 12 weeks and Mean LDL-C change at Weeks 10 and 12 compared to Placebo. Started Nov 2024; status: recruiting.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06568471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568471.